乌司他丁在儿童脓毒症治疗中的临床应用研究

Study on Clinical Application of Ulinastatin in Treatment of Children with Sepsis

目的探讨乌司他丁在儿童脓毒症临床治疗中的应用效果。方法选择2015年1月—2017年1月宁夏医科大学总医院PICU收治的100例脓毒症患儿,给予对照组(n=50)患儿常规治疗,应用抗菌药物、对症治疗等。在此基础上,给予观察组(n=50)乌司他丁,连续治疗5 d后,评估两组患儿的全身炎症指标的改善情况、临床指标与小儿危重病例评分(PCIS)。结果治疗后第1 d,观察组患儿的体温、C反应蛋白、PCIS评分即有明显改善,分别为(38.43±0.18)℃、(60.33±2.16)mg/L、(12.52±1.69)×10~9/L;对照组治疗后1 d分别为(39.15±0.38)℃、(66.57±5.38)mg/L、(14.68±1.35)×10~9/L,比较差异有统计学意义(P<0.05)。两组患儿均未发生肝肾功能、凝血功能异常等并发症(P>0.05)。结论在常规治疗的基础上联合乌司他丁,可迅速改善脓毒症患儿的临床症状与体征,安全有效,建议推广。

Objective To study the application effect of ulinastatin in treatment of children with sepsis. Methods 100 cases of children with sepsis admitted and treated in our hospital from January 2015 to January 2017 were selected and divided into two groups with 50 cases in each, the control group used the routine therapy, while the observation group used the ulinastatin on the basis of the routine therapy, and the improvement of systemic inflammatory markers, clinical indicators and PCIS of the two groups were evaluated after 5d in a row. Results The body temperature, C reactive protein and PCIS score in the observation group were obviously improved on 1d after treatment, respectively (38.43±0.18)℃,(60.33±2.16)mg/L,(12.52±1.69)×109/L; in the control group, respectively (39.15±0.38)℃,(66.57±5.38)mg/L,(14.68±1.35)×109/L, and the differences between groups were obvious (P<0.05), and there were no complications such as abnormal liver and kidney function and coagulation function(P>0.05). Conclusion The ulinastatin on the basis of the routine therapy can rapidly improve the clinical symptoms and vital signs of children, and it is safe and effective, and it is suggested to be promoted.